Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | ESRRA | P11474 | 3/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30280499 | 1.00 | NOTUM (0.55) | NOTUMESRRAGRM1GRM5CA5A | |
| SCHEMBL2220827 | 0.86 | NOTUM (0.56) | NOTUMESRRAGRM1GRM5CA5A | |
| SCHEMBL30398923 | 0.84 | NOTUM (0.55) | NOTUMESRRAGRM1GRM5CA5A | |
| SCHEMBL28033304 | 0.84 | NOTUM (0.55) | NOTUMESRRAGRM1GRM5CA5A | |
| SCHEMBL20263260 | 0.82 | ACKR3 (0.52) | SMN1; SMN2 | |
| SCHEMBL17365300 | 0.81 | RXRA (0.48) | NOTUMESRRAKMT2AGSK3BSMN1; SMN2 | |
| SCHEMBL1422761 | 0.80 | ALDH1A1 (0.54) | NOTUMESRRACA2CA9NPSR1 | |
| SCHEMBL15933192 | 0.80 | RXRA (0.48) | — | |
| SCHEMBL17454512 | 0.79 | ESRRA (0.48) | NOTUMESRRAGRM1GRM5CA5A | |
| SCHEMBL23889183 | 0.77 | ESRRA (0.59) | NOTUMESRRACA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3554506-B1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190330219-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | PFIZER INC. | 2019-10-31 | — | — | US | disclosed |
| EP-3554506-A1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation Therapeutics, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10377762-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10131670-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| WO-2018112149-A1 | BYCYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATON THERAPEUTICS INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377762-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RY2 | NOTUM 2987/4885ESRRA 1916/4885GRM1 1545/4885 |
| US-10208053-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RX3 | NOTUM 3382/4885ESRRA 1873/4885GRM1 1948/4885 |
| US-20190330219-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, SLC26A3, P2RY2 | NOTUM 2987/4885ESRRA 1916/4885GRM1 1545/4885 |
| US-20190016728-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | NOTUM 3428/4885ESRRA 2508/4885GRM1 1450/4885 |
| US-10131670-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, P2RY2, P2RX5 | NOTUM 3428/4885ESRRA 2508/4885GRM1 1450/4885 |
| US-20180170938-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | NOTUM 3428/4885ESRRA 2508/4885GRM1 1450/4885 |
| US-20190016727-A1 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | CFTR, P2RY2, P2RX5 | NOTUM 3428/4885ESRRA 2508/4885GRM1 1450/4885 |
| US-10766904-B2 | Bicyclic heteroaryl derivatives as CFTR potentiators | CFTR, SLC26A3, P2RY2 | NOTUM 2987/4885ESRRA 1916/4885GRM1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.